Close Menu

George Davis

Feb 17, 2017

Perthera has appointed George Davis to its board of directors. Davis currently serves as CEO of Gemstone Biotherapeutics. Previously, he served as president and vice chairman of Aether Systems. He has also served as CEO and director of Avatech Solutions.

More Like This

Aug 22, 2019

Color: Jill Hagenkord

Jill Hagenkord is no longer chief medical officer of genetic testing firm Color, and has started a new consulting company, called MDisrupt. Hagenkord previously held executive positions at Invitae, 23andMe, and Complete Genomics. She co-founded MDisrupt with another 23andMe alum, Ruby Gadelrab, who is serving as CEO. The start-up describes itself as a "medical diligence company" that aims to help companies speed innovative products to market by "assessing a product's clinical and commercial viability in a healthcare setting."

Aug 21, 2019

PerkinElmer: Robert Friel, Prahlad Singh, Alexis Michas

After serving 12 years as CEO of PerkinElmer, Robert Friel will step down from that position as well as from his role as chairman of the board, effective Dec. 29, 2019. He will continue to serve as an advisor until March 1, 2020. The firm also announced that Prahlad Singh, current president and COO of PerkinElmer, will become CEO on Dec. 30, 2019, and he has been elected a director of the company, effective today. Prior to joining PerkinElmer in 2014, Singh was general manager of GE Healthcare's women's health business.

PerkinElmer also said that Alexis Michas, currently lead director, will serve as non-executive chairman of PerkinElmer's board, starting Dec. 30.

Aug 15, 2019

ViroGates: Mark Christian Hvidberg da Silva

Danish blood test systems developer ViroGates announced that Mark Christian Hvidberg da Silva is joining the firm as CFO, effective Oct. 1. Its former CFO, May Britt Dyvelkov, will remain at the company as vice president of accounting. da Silva joins ViroGates from management consulting firm Qvartz where he was a manager. He previously was at Novozymes and Nova Founders Capital. 

Aug 15, 2019

Aperiomics: C. Alexander Valencia

C. Alexander Valencia has joined Aperiomics as Chief Clinical Officer. He will oversee the microorganism sequencing firm's clinical test development, validations, regulatory affairs, and operations.

Prior to joining Aperiomics, Valencia served as molecular laboratory director at Cincinnati Children's Hospital Medical Center. He has experience at PerkinElmer Genomics. He holds a doctorate from Canada's Carleton University and the University of Ottawa and held post-doctoral positions in biochemistry and molecular biology at the University of North Carolina at Chapel Hill and in clinical molecular genetics at Emory University.

Aug 14, 2019

OraSure Technologies: James Datin

OraSure Technologies has appointed James Datin to its board. He will serve as a Class III director with his initial term expiring at the company's 2021 shareholders' meeting. He will serve on OraSure's audit and compensation committees. Datin is president and CEO of BioAgilytix, a global bioanalytical contract research organization which supports the development of therapeutic biologics. Prior to that, he was executive vice president and managing director at Safeguard Scientifics. 

Aug 13, 2019

Biodesix: Robert Georgantas III

Robert Georgantas III was appointed by Biodesix as its senior vice president of research and translational science. He was formerly director of immunology programs, genomics, and the Genetics Research Center of Excellence at AbbVie. Prior to that, he was a senior scientist in the department of translational sciences at Medimmune. 

Aug 09, 2019

NeoGenomics: Sharon Virag

NeoGenomics said in a document filed with the US Securities and Exchange Commission that CFO Sharon Virag has resigned from the company, effective immediately. NeoGenomics did not provide additional details. It will begin a search for her replacement "in due course," it said.

Aug 08, 2019

Accelerate Diagnostics: Jack Phillips

Tucson, Arizona-based Accelerate Diagnostics has named Jack Phillips its new COO. Phillips most recently served as president and CEO of Roche Diagnostics North America. He was senior VP and GM of Ventana Medical Systems prior to the tissue diagnostics firm being acquired by Roche in 2008.

Aug 08, 2019

Veravas: Carroll Streetman

Charleston, South Carolina-based Veravas has appointed Carroll Streetman Jr. as CEO. Streetman previously served as president at Full Spectrum Behavior Analysis and will remain on the firm's board. Prior to Full Spectrum, Streetman served as president at DiaSorin Inc. He has also served as president and managing partner of CSHC Consultants. Prior to CSHC, he was chief operating officer of HCA Healthcare.

Aug 07, 2019

Progenity: Brian Kotzin

Progenity has appointed Brian Kotzin to its board of directors. Kotzin is currently on the board of directors for Rigel, and serves as a principal fellow and senior vice president for Nektar Therapeutics. His previous roles include vice president of global clinical development and head of the inflammation therapeutic area, and vice president and head of medical sciences at Amgen. Prior to entering the life sciences industry, he held several professorships at the University of Colorado Health Sciences Center, where his research focused on immunopathogenesis of disease.

Aug 06, 2019

Invitae: Randy Scott, Sean George

Invitae announced that Randy Scott will retire as executive chairman from its board of directors effective September 1. Invitae CEO Sean George will be the board's new chairman at that time. Scott served as CEO of Invitae between 2012 and 2017, after which George took over the reins. Scott said in a statement that he plans to continue to support the Invitae team as a private investor.

Aug 05, 2019

Foundation Medicine: Priti Hegde

Priti Hegde has been appointed as CSO of Foundation Medicine, a Roche company, effective August 5. She replaces Michael Doherty, who will be retiring in September. Previously, she held various posts at Genentech, where she was most recently senior director and principal scientist in oncology biomarker development. Prior to that, she was manager of disease and biomarker transcriptomics at GlaxoSmithKline. Hegde holds a PhD in biochemical pharmacology from SUNY Buffalo and a B. Pharmacy degree from Mumbai University in India.

Aug 05, 2019

Roche Diagnostics Canada: Andrew Plank

Andrew Plank has been appointed as president and general manager of Roche Diagnostics Canada, a division of Roche. Previously, he was global VP and international business leader in Roche Diagnostics' Centralized and Point of Care Solutions division in Switzerland.

Aug 05, 2019

Fulgent Genetics: Linda Marsh

Temple City, California-based Fulgent Genetics has appointed Linda Marsh to its board of directors. Marsh currently serves as senior executive VP at AHMC Healthcare and is a board member at Apollo Medical Holdings. In addition, she is a board member of the Hospital Association of Southern California, a board member of Private Essential Access Community Hospitals, and a board member of the American Red Cross.

Aug 01, 2019

Siemens Healthineers: Bernd Montag, Michael Reitermann, Christoph Zindel

Erlangen, Germany-based Siemens Healthineers announced that Michael Reitermann, a member of the managing board responsible for its Diagnostics business segment and its regional sales and service organization, will step down from his post on Sept. 30 and leave the company.

Starting Oct. 1, the firm's CEO Bernd Montag will be responsible for the Diagnostics business segment, the Enterprise Services and Customer Services business horizontals, and for the Americas; Europe, Middle East and Africa; and Asia-Pacific regions.

Christoph Zindel, head of Diagnostic Imaging since October 2018, will become a member of its managing board effective Oct. 1. Zindel will take over responsibility for the Imaging business segment and the Advanced Therapies business segment.